CTICasesCystic Fibrosis Improvement with Trikafta
Imaging findings
Serial chest radiographs and CT chest scans in a cystic fibrosis patient show significant clearing of mucus plugging, reduction in bronchiectasis severity, and decreased bronchial wall thickening following the initiation of Trikafta therapy.
Key takeaways
Trikafta (elexacaftor/tezacaftor/ivacaftor) is a highly effective CFTR modulator. It has revolutionized cystic fibrosis management, leading to rapid, dramatic improvement in structural imaging findings on chest radiographs and CT, which correlates with improved pulmonary function.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Pulmonary Artery Pseudoaneurysm post-Aspergillus MycetomaCongenital
- Pembrolizumab-Induced Diaphragmatic Crus AtrophyIatrogenic
- Klebsiella Septic Embolism with Bird's Nest SignInfection
- Late Pleural Recurrence of ThymomaNeoplastic
- Staphylococcus Aureus Septic Arthritis with Septic EmboliInfection
- Strongyloides Hyperinfection SyndromeInfection
- Right Ventricular Insertion Point LGE in AthletesOther
- Idiopathic Bronchial CalcificationInflammatory
See all cases from October 8, 2021 →
Related Congenital cases
- Hermansky-Pudlak Syndrome
- Absent Right Upper Fissure
- Bilateral Ductus Arteriosus (with Atresia of Right Pulmonary Artery Connection)
- Neurofibromatosis Type 1 (NF1) with Ribbon Ribs and Dural Ectasia
- Aberrant Bronchial Artery from Left Subclavian Artery and Left Atrial Diverticulum
- Bronchopulmonary Sequestration (Hybrid Lesion with Bronchial Atresia)